藥明康德(02359.HK)3.48萬股限制性A股解除限售期
格隆匯3月1日丨藥明康德(02359.HK)宣佈,根據2019年A股激勵計劃的條款,特別授予四批限制性A股股票的限售期分別為自登記日期起至2021年2月28日、2022年2月28日、2023年2月28日及2024年2月29日。
第一個限售期於2021年2月28日屆滿,並於2021年3月1日進入第一個解除限售期。獲特別授予限制性A股股票的調整後激勵對象有權於達成若干特定條件後就其所持20%限制性A股股票申請解除限售期。上述解除限售的3.48萬股限制性A股股票於2021年3月5日開始上市及買賣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.